Shreya Kanodia, PhD

Planning Director for Cancer Grants, Biomedical Sciences

Associate Director for Administration, Cancer Institute

Email:Shreya.Kanodia@cshs.org
Phone:(310) 423-3596
Fax:(310) 423-8300

Institute Affiliation

Cancer Institute

Academic Appointments

Assistant Professor, Biomedical Sciences

Awards and Activities

NIH Travel Award-International Papillomavirus Society2009 - 2010
USC Norris Cancer Center Distinguished Merit Award2008 - 2009
NIH Travel Award-International Papillomavirus Society2006 - 2007
Vivian L. Smith Outstanding Young Immunologist Award2004 - 2005
American Legion Auxilary Fellowship2003 - 2005
Sowell-Huggins/Sylvan Rodriguez Fellowship2003 - 2004
American Society of Hematology Travel Award2002 - 2003
MD Anderson Cancer Center Trainee Excellence Award2002 - 2003
GSBS Student Travel Award2001 - 2003
Women's Travel Scholarship Award2001 - 2002
Oncology ReviewsCurrent
Journal of ImmunotherapyCurrent
Current Pharmaceutical DesignCurrent
Clinical and Developmental ImmunologyCurrent
Cancer ResearchCurrent
Association of American Cancer Institutes/Cancer Center Administrators Forum2010
American Association of Cancer Research2013
National Council of University Research Administrators2013

Research Focus

Pathogenesis and immunotherapy of cervical tumors, prostate tumors and mesothelioma.

Selected Publications

  1. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin. Cancer Res., 18(19): 5352-63, 2012
  2. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, Tuncer M, Way S, Yang H, Miller A: Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc. Natl. Acad. Sci. U.S.A., 108(33): 13618-23, 2011
  3. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM: Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res., 70(10): 3955-64, 2010
  4. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ: PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS ONE, 5(7): e11770, 2010
  5. Kanodia S, Kast WM: Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines, 7(10): 1533-45, 2008
  6. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM: Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest., 111(5): 639-47, 2003